Friday, 7 February 2020

Colposcopy Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023

Global Colposcopy Market Research Report: Instrument Type (Optical Colposcope, Digital Colposcope), Instrument Portability (Portable, Fixed, Handheld), Application (Cancer Screening, Examinations), Magnification Type, End-User – Global Forecast Till 2023
Market Scenario
A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.
For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.
The Global Colposcopy Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.
Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.
Segmentation
The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.
On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.
On the basis of instrument portability, the market is classified into portable, fixed, and handheld.
On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.
On the basis of magnification type, the market is classified into fixed magnification and variable magnification
On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.
The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 
The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.
The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.
The Americas is likely to dominate the global colposcopy market trends owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.
Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  
The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.
Company Profiles            
  • Carl Zeiss
  • Olympus Corporation
  • Danaher Corporation
  • Philips Healthcare
  • CooperSurgical
  • McKesson Corporation
  • DYSIS Medical
  • Atmos
  • Alliton
  • Seliga Microscopes
  • Karl Kaps
  • Bovie Medical
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora, Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Electronic Pill Market Robust Expansion by Top Key Players, Demand and Supply to 2023

Global Electronic Pill Market Research Report, By Application (Capsule Endoscopy, Drug Delivery), Target Area (Oesophagus, Stomach), Parts (Biocompatible Capsule Encasing Microsensors), End-User (Diagnostics Centers, Hospitals) – Global Forecast Till 2023
Market Scenario
Electronic pills are equipped with sensors and cameras which allow capturing of several images of the gastrointestinal tract. They are used for diagnostic purposes and are increasingly replacing traditional diagnostic methods. It further monitors various parameters such as temperature, conductivity, pH, and dissolved oxygen. Market Research Future (MRFR) has thoroughly studied the trends and patterns governing the global electronic pills market over the forecast period of 2018-2023 in a detailed study. MRFR projects a CAGR of 15% within the electronic pills market over the forecast period.
Towering prevalence of gastrointestinal disorders has driven the market for electronic pills. Electronic pills alleviate tedious and painful diagnostic procedures such as colonoscopy and endoscopy and provide accurate results without much discomfort to the patient. Surging cases of stomach cancer coupled with increasing preference for minimally invasive medical procedures is likely to augment the growth of the electronic pills market. Healthcare professionals are increasingly adopting theses pills as they facilitate on-site diagnosis. Other factors which contribute to the growth of the market include improving reimbursement scenario and rise in global geriatric population who are more susceptible to various chronic diseases. Additionally, capsule endoscopy has gained widespread adoption as a non-invasive diagnostic method which is likely to fuel the growth of the market over the forecast period with new Electronic Pill Market Technology. On the contrary, the growth of the electronic pills market can be impeded by factors such as lack of awareness, capsule retention, and bowel obstruction. Moreover, high costs aligned with electronic pills and regulatory restrictions are anticipated to hinder the growth of the market.
Segmentation
The global electronic pill market has been segmented based on application, target area, part, and end user.
By application, the electronic pill market has been segmented into capsule endoscopy, drug delivery, and patient monitoring.
By target area, the electronic pill market has been segmented into oesophagus, stomach, small intestine, and large intestine.
By part, the electronic pill market has been segmented into biocompatible capsule encasing microsensors, control chip, radio transmitter and power source.
By end user, the electronic pill market has been segmented into Hospitals, diagnostic centers, clinical research organizations, and medical centers.
Regional Analysis
By region, the electronic pill market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
In 2017, the global electronic pill market was led by the Americas. The dominance of the Americas market can be attributed to the surging prevalence of gastrointestinal diseases, vigorous R&D activities and fast uptake of the latest technologies in the region.
Europe follows the Americas closely and is estimated to showcase substantial growth over the forecast period. Escalating cases of gastric cancer and high demand for diagnostics services is fuelling the growth of the market.
The APAC electronic market is likely to witness the fastest growth over the forecast period. The growth of the market can be attributed to increasing patient population, growing medical tourism in the region, and extensive R&D activities and high investment by the governments in the region create a conducive environment for the growth of the market.
The MEA market accounts for the least share of the electronic pill market. The growth of the market might be restrained by stringent government policies and poor economic conditions.
Competitive Landscape
Medtronic, JINSHAN Science & Technology, Medimetrics (Mexico), Medisafe, CapsoVision, Inc. (US), Given Imaging Ltd. (Israel), (Bio-Images Drug Delivery) BDD LTD (UK), Proteus Digital Health (US), Olympus Corporation, and INTROMEDIC are the distinguished players in the electronic pill market.
Industry Updates
February 2019 - a new electronic pill equipped with Wi-Fi transmitter has been developed which is capable of harvesting energy from inside a patient's stomach and record core body temperature and then send data to an external monitor.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Immunofluorescence Assay Market 2019 Global Growth Opportunities, Key Driving Factors, Industry Scenario and Forecast to 2023

Market Scenario
The growing prevalence of chronic and infectious diseases increase in research and development activities, growing government investments for R&D activities, increased need for rapid and sensitive diagnostics, and adoption of technologically advanced systems are the key factors for the market to grow. However, factors such as, expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
The Global Immunofluorescence Assays Market Size is expected to reach an approximate CAGR of 5.8% during the forecast period.
According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease.  Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.
However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
Key Players
Some of the key players for the global Immunofluorescence Assay market are Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc.,BioTek Instruments,Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc. Becton Dickinson and Company , Merck , Agilent Technologies , TCS Biosciences Ltd, Maxvision Biosciences Inc. and Others.
Segmentation
The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique is sub segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and micro immunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method and double staining method. On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labelling dyes and species type. Instruments is further sub segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.
Regional Market Summary
The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.
It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.
The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Thursday, 6 February 2020

Acute Care EHR Market Comprehensive Overview, Industry Size, Booming Share, Key Players Review, Phenomenal Growth and Business Boosting Strategies till 2023

Acute Care Electronic Health Recorder (EHR) Market Research Report- Information By Deployment (On-Premise Based, Cloud-Based), By Application (Personal Care, Pharmaceuticals), and By End User (Hospitals, Ambulatory Care) - Global Forecast till 2023
Acute care EHR is different from its traditional counterparts. The acute care EHR allows healthcare professionals to collect, preserve and access vital patient clinical data in acute care and ambulatory care settings. Market Research Future (MRFR) perceives the global acute care EHR market to register a CAGR of 7% over the forecast period of 2017-2023.
The global acute care EHR market growth driven by the surging incidences of chronic diseases on a global scale. In recent years, the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease have been on the rise which has consequently raised the number of healthcare institutions. Growth in a number of hospitals and other medical centers have created massive demand for management of patient data which boosts the growth of the global acute care EHR market. The rise in global geriatric population is also a contributing factor to the growth of the global acute care EHR market. The aged population who are more susceptible to suffer from chronic diseases have induced high demand for remote monitoring of geriatric patient data. Factors such as development in healthcare IT, technological advancements and expanding expenditure on healthcare act as a plus for the growth of the market. On the contrary, the growth of the global acute care EHR market might be restrained by high costs associated with acute care EHR solutions which might limit the growth of the market in price-sensitive market. Furthermore, towering costs of healthcare devices and treatments are also likely to hinder market growth.
Competitive Landscape
The noteworthy players in the global acute care EHR market include Epic Systems Corporation (U.S.), Evident (CPSI) (U.S.), eClinicalWorks (U.S.), Medhost (U.S.), Athenahealth (RazorInsights) (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), Meditech (U.S.), McKesson Corporation (U.S.), Allscript (U.S.), Cerner Corporation (Siemens) (U.S.), Healthland (U.S.), and General Electric Company (U.S.).
Segmentation
The global acute care EHR market has been segmented based on deployment, application, and end user.
By deployment, the global acute care EHR market has been segmented into On-Premises based and Web-based.
By application, the global acute care EHR market has been segmented into personal care, pharmaceuticals, and others.
By end user, the global acute care EHR market has been segmented into hospital, ambulatory care, and others.
Regional Analysis
The Americas dominate the global acute care EHR market owing to the increasing number of hospitals ambulatory centers, presence of huge patient population and well developed technology. The hospital and clinics are able to afford the cost of the devices as these are funded by several sources: the public sector, charities, health insurance companies, health organizations of all kinds, etc. Additionally, the people in this region are able to afford high cost of treatment on account of higher per capita income in this region. Rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better devices which has driven the growth of the market. Moreover, well developed technology, high healthcare expenditure, and huge geriatric population have fuelled the growth of the market in this region.
Asia Pacific is the fastest growing acute care EHR market owing to the increasing number of patients suffering from chronic diseases and rapidly increasing number of hospitals & clinics. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.
Europe commands the second largest market for acute care EHR which is followed by Asia Pacific. Availability of funds, strong government support, and increasing need for the better management devices & platform drive the growth of the market in Europe. Western Europe holds a major share of the market due to the presence of well developed economies. U.K, Germany and France are the major contributors of the market.
Industry Updates
  • In November 2018, ResMed, a company that specializes in connected devices and remote monitoring for sleep apnea and respiratory illnesses announced the acquisition of MatrixCare’s post-acute care EHR solution for USD 750 million.
  • In December 2018, Allscripts, a provider of healthcare solutions, announced selling of its stake in post-acute care EHR vendor Netsmart to TA Associates and GI Partners, both private equity firms for a total amount of USD 525 million.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Retropharyngeal Abscess Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

Retropharyngeal abscess market research report: information by diagnosis (X-rays and computed tomography, blood tests, physical exam, others), by treatment (antibiotics, pain killers, surgical drainage, others), and by end-user– Global forecast till 2023
Market scenario:
Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.
The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.
The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.
Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.
Segments
The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.
Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.
Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Regional Analysis
Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Key Players
  • Merck KGaA,
  • Johnson & Johnson,
  • AstraZeneca plc,
  • Sanofi S.A.,
  • Pfizer,
  • Mylan N.V,
  • Novartis AG,
  • Teva pharmaceutical company,
  • GlaxoSmithKline plc.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Encephalomyelitis Market Growing prevalence of genetic disorder, Top Trends, Key Players Growth Analysis, Regional Opportunity, Market Share, Demand Overview 2019 – 2023

Encephalomyelitis Market Research Report–Type (Acute Disseminated Encephalomyelitis, Encephalomyelitis Disseminata, Antimog Associated, AIDS Related Encephalomyelitis), Treatment (Drug Treatment, Surgery), End User (Hospital) - Global Forecast till 2023                                                                                                                          
Market Scenario
Encephalomyelitis is brain or spinal cord inflammation caused due to virus, infections, and other foreign particles. The patient suffering from autoimmune diseases and AIDS are more prone to the diseases. A wide range of drugs are available for the treatment of this disease, however no precise treatment is available to cure the disease. Increasing prevalence of encephalomyelitis and autoimmune diseases has boosted the growth of the market. According to the WHO, 4.3 million people across the globe are affected by this disease. Additionally, changing lifestyle, increasing geriatric population, increasing need for better treatment has driven the global market. Moreover, increasing government support along with the per capita income have fuelled the market growth. However, limited and high cost of treatment options may retard the growth of the market over the assessment period.
The global encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 
Segmentations
The global encephalomyelitis market is segmented on the basis of types, treatment and end users.
On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.
On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.
On the basis of end users, the market is segmented into hospital, clinics and others.
Regional Analysis
The Americas command a major of the Encephalomyelitis market share owing to the large patient population, growing prevalence of encephalomyelitis & autoimmune diseases, and strong government support for research & development. According to the American Autoimmune Related Diseases Association, approximately 50 million people in the U.S. were reported to be suffering from autoimmune diseases in 2014.
Europe accounts for the second largest market across the globe, which is followed by Asia Pacific. Strong government support, availability of funds for research and high healthcare expenditure drives the growth of the market. Asia Pacific is the fastest growing market. China, and India are the key contributors to the market growth due to presence of huge population base, increasing prevalence of AIDS and autoimmune diseases, rapidly growing economy, and increasing healthcare expenditure. Additionally, increasing government support, and presence of huge opportunity have fuelled the growth of the market in Asia Pacific.
The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market owing to the well-developed economy and high healthcare spending.
Key Players
Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Medical Tricorder Market Overview - Key Futuristic Trends and Opportunities

Global Medical Tricorder Information, By Type (USB Camera, Fiber Optic Camera, Wireless, Corded, others), By Application (Diagnosis, Monitoring, others), By End Users (Hospitals, Clinics and others) - Forecast to 2023
Market Synopsis of Global Medical Tricorder Market
Medical device used by the consumer to self-diagnose medical condition is known as a medical tricorder. It takes basic vital measurement like heart rate and body temperature within seconds. Major functions of a medical tricorder are to monitor health of a person, summarize patient’s health, diagnose disease and take health measurements. Furthermore, rapid development in technology, increasing government support for research & development, changing lifestyle, and many adverse effects of the present diagnostic methods expected to fuel the market growth during the forecast period.
Medical Device Industry is flourishing across the globe owing to an increasing demand for technologically advanced devices, extensive use of smart medical devices, and overall improvement in healthcare sector. Various smart devices are used to determine the heart rate, glucose levels in the body, and other parameters.
Global medical tricorder market is expected to reach USD 5.4 billion in 2023 from USD 2.5 billion in 2016 with a CAGR of approximately 6.7% during the forecast period 2017-2023.
However, these types of devices has to pass all the regulatory standards and rules, which increases the approval time. The average approval time for the medical diagnostic device may vary from 5-8 years. This long approval time, high cost of the research & development and devices may hamper the market growth during the corresponding period.
The demand of medical tricorder is increasing because of an increase in the demand medical tricorder among health care providers, helping them to diagnose patient’s health condition, increasing outpatient services in the hospitals, increase in patient pool suffering from diabetes, and cardiovascular diseases, and demand for new technology for diagnoses and monitoring.
According to findings from the WHO, in 2014, approximately 422 million people suffered from diabetes across the globe.

Global Medical Tricorder Market – Regional:
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
America is the largest market which is attributed to extensive use of medical tricorder by number of physicians in America. Increasing in patient pool, increase in outpatient services and concentration of major market players of medical tricorder in North America drive this market in America. North America is the largest market whose growth is attributed to an increase in patient pool, and demand for improved technology for diagnosis of ongoing health of a patient drive this market in America. According to the American Diabetes Association, in 2015, approximately 30.3 million Americans which is 9.4% of the American population were suffering from diabetes 
The European market is also growing continuously and slowly catching up with the American market in the near future. Emphasis for early diagnosis of disease condition and awareness regarding the use of tricorder. Extensive research in innovative product development, and adoption of new technologies in healthcare institutes such as hospitals & clinics, research institutes, clinical laboratories, diagnostics center and home care settings. QuantuMDx Group Ltd. is in Europe. It is one of the major market players for medical tricorder, thus favoring the opportunities for research and development activities in the field of medical devices and molecular diagnosis.
Asia-Pacific market is expected to show steady growth in the medical tricorder market during the forecasted period owing to the rising prevalence of chronic diseases such as obesity, diabetes, cardiovascular diseases, growing geriatric population, and development in healthcare sector. China and India are expected to be the emerging market in Asia Pacific, owing to the increasing number of patients diagnosed with chronic diseases, and high growth potentials supported by favourable macro-economic conditions.
Middle East & Africa show slow growth in this market owing to demand for primary care services for the diagnosis and treatment of chronic diseases, and rising awareness about preventive measures for various diseases, and increasing emphasis on women and child care.
Global Medical Tricorder Market: Company Analysis
Ibis Biosciences, Inc. provides molecular diagnostics, offers instruments and reagents to analyze DNA and RNA for clinical specialists and laboratory. In February 2016, the company won a USD 2,124,718 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia for R&D.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)